Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysisPatricia Cortazar, Gϋnter von Minckwitz, Sandra M. Swain et al.|The Lancet|2014Cited by 4.7k
FDA Approval Summary: Olaparib Monotherapy in Patients with Deleterious Germline <i>BRCA</i>-Mutated Advanced Ovarian Cancer Treated with Three or More Lines of ChemotherapyGeoffrey Kim, Richard Pazdur, Gwynn Ison et al.|Clinical Cancer Research|2015Cited by 526
Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell CarcinomaVicki Goodman, Richard Pazdur, Edwin P. Rock et al.|Clinical Cancer Research|2007Cited by 495
Sorafenib for the Treatment of Advanced Renal Cell CarcinomaRobert C. Kane, Richard Pazdur, Ann T. Farrell et al.|Clinical Cancer Research|2006Cited by 466
FDA Approval Summary: Vorasidenib for <i>IDH</i> -Mutant Grade 2 Astrocytoma or Oligodendroglioma Following SurgeryMichael I. Barbato, Nicole Drezner, Amy Barone et al.|Clinical Cancer Research|2025Cited by 9